BIOGEN INC. - COMMON STOCK

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

30 Jun 2025 04:30:12 By Nasdaq GlobeNewswire

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

27 Jun 2025 07:00:23 By Nasdaq GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

25 Jun 2025 04:30:37 By Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

18 Jun 2025 04:30:27 By Nasdaq GlobeNewswire

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

11 Jun 2025 22:00:39 By Nasdaq GlobeNewswire

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

27 May 2025 04:30:00 By Nasdaq GlobeNewswire

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

15 Apr 2025 16:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

09 Apr 2025 06:45:15 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

08 Apr 2025 10:06:04 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

07 Apr 2025 06:45:03 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

04 Apr 2025 06:47:36 By NetDania Notify

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

02 Apr 2025 04:30:00 By Nasdaq GlobeNewswire

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

24 Mar 2025 04:30:00 By Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

11 Mar 2025 04:30:00 By Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

18 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

12 Feb 2025 06:45:10 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

11 Feb 2025 08:11:08 By NetDania Notify

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

31 Jan 2025 03:30:52 By Nasdaq GlobeNewswire

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

26 Jan 2025 15:33:52 By Nasdaq GlobeNewswire

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

23 Jan 2025 04:30:54 By Nasdaq GlobeNewswire